Organon: Revenue Decline, Margin Pressure, And Strategic Uncertainty
Source: SeekingAlpha
2026-02-22 04:56:59 ET
Investment thesis
Read the full article on Seeking Alpha
For further details see:
Organon: Revenue Decline, Margin Pressure, And Strategic Uncertainty
Organon & Co.
NASDAQ: OGN
OGN Trading
0.31% G/L:
$6.48 Last:
1,477,572 Volume:
$6.56 Open:
OGN Latest News
February 27, 2026 08:00:00 am
New Analysis of Organon's VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
February 23, 2026 07:30:00 am
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device
OGN Stock Data
$2,031,766,457
254,887,247
0.05%
304
N/A
Pharmaceuticals
Healthcare
US
Jersey City
